Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Mar 24;12(3):e0174222.
doi: 10.1371/journal.pone.0174222. eCollection 2017.

Timely meta-analysis on the efficacy of adoptive immunotherapy for hepatocellular carcinoma patients after curative therapy

Han-Yue Mo  1 , Ying-Yang Liao  2 , Xue-Mei You  3   4 , Alessandro Cucchetti  5 , Bao-Hong Yuan  6 , Ru-Hong Li  6 , Jian-Hong Zhong  3   4 , Le-Qun Li  3   4
Affiliations
Meta-Analysis

Timely meta-analysis on the efficacy of adoptive immunotherapy for hepatocellular carcinoma patients after curative therapy

Han-Yue Mo et al. PLoS One. .

Abstract

Aims: The role of adoptive immunotherapy (AIT) for patients with hepatocellular carcinoma (HCC) who have received curative therapy is still not well illustrated. This timely meta-analysis aims to update the current evidence on efficacy and safety of AIT for patients with HCC who have received curative therapy.

Methods: We searched PubMed, EMBASE, Scopus and the Cochrane Library Through January 2017 for relevant studies. Mortality and tumor recurrence were compared between patients with or without adjuvant AIT. The meta-analysis was performed using Review Manager 5.3.

Results: Eight studies involving 1861 patients met the eligibility criteria and were meta-analyzed. Adjuvant AIT was associated with significantly lower mortality at 1 year (RR 0.64, 95%CI 0.52-0.79), 3 years (RR 0.73, 95%CI 0.65-0.81) and 5 years (RR 0.86, 95%CI 0.79-0.94). Similarly, adjuvant AIT was associated with significantly lower recurrence rate than curative therapies alone at 1 year (RR 0.64, 95%CI 0.49-0.82), 3 years (RR 0.85, 95%CI 0.79-0.91) and 5 years (RR 0.90, 95%CI 0.85-0.95). Short-term outcomes were confirmed in sensitivity analyses based on randomized trials or choice of random- or fixed-effect meta-analysis model. None of the included patients experienced grade 4 adverse events.

Conclusions: This timely meta-analysis confirms the evidence that adjuvant AIT for patients with HCC after curative treatment lowers risk of mortality and tumor recurrence.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flow chart of study selection.
Fig 2
Fig 2. One year recurrence rate of meta-analysis comparing the efficacy of adjuvant adoptive immunotherapy (AIT) with curative treatment alone.
Fig 3
Fig 3. One year mortality of meta-analysis comparing the efficacy of adjuvant adoptive immunotherapy (AIT) with curative treatment alone.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel RL, Miller KD, Jemal A (2017) Cancer Statistics, 2017. CA Cancer J Clin 67: 7–30. 10.3322/caac.21387 - DOI - PubMed
    1. Zhong JH, Peng NF, You XM, Ma L, Xiang X, Wang YY, et al. (2017) Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: A real-world study. Oncotarget: [Epub ahead of print]. - PMC - PubMed
    1. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer 48: 599–641. 10.1016/j.ejca.2011.12.021 - DOI - PubMed
    1. Lim KC, Chow PK, Allen JC, Siddiqui FJ, Chan ES, Tan SB. (2012) Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria. Br J Surg 99: 1622–1629. 10.1002/bjs.8915 - DOI - PubMed
    1. Guo Z, Zhong JH, Jiang JH, Zhang J, Xiang BD, Li LQ. (2014) Comparison of survival of patients with BCLC stage A hepatocellular carcinoma after hepatic resection or transarterial chemoembolization: a propensity score-based analysis. Ann Surg Oncol 21: 3069–3076. 10.1245/s10434-014-3704-8 - DOI - PubMed

Publication types